Quoin Pharmaceuticals, LTD 8-K filings

Quoin Pharmaceuticals has announced the pricing of a $6.8 million public offering, including shares, warrants, and pre-funded warrants, to fund general corporate purposes and research.

Quoin Pharmaceuticals has received FDA clearance to initiate a new clinical study for QRX003, a topical lotion for Netherton Syndrome, involving whole-body application.

Quoin Pharmaceuticals shareholders approved amendments to the company's articles of association and compensation programs for key executives at the 2024 Annual General Meeting.

Quoin Pharmaceuticals reports its third quarter 2024 financial results, initiates a Peeling Skin Syndrome clinical program, and expands its Netherton Syndrome clinical trials internationally.

Quoin Pharmaceuticals has been granted an additional 180 days, until April 28, 2025, by Nasdaq to regain compliance with the minimum bid price requirement.

Quoin Pharmaceuticals has announced its 2024 Annual General Meeting date as December 5, 2024, and revised the deadlines for shareholder proposals.

Quoin Pharmaceuticals reports its second quarter 2024 financial results, expands clinical trials internationally, and broadens its product portfolio through a new research agreement.

Quoin Pharmaceuticals has been notified by Nasdaq that its American Depositary Shares have fallen below the minimum bid price requirement, triggering a potential delisting process.

Quoin Pharmaceuticals shareholders approved a proposal to issue shares related to a purchase agreement with Alumni Capital LP at a special meeting held on April 5, 2024.

Quoin Pharmaceuticals reports positive initial clinical data for its Netherton Syndrome treatment, QRX003, and secures funding to extend its cash runway into the second half of 2025.

Quoin Pharmaceuticals has successfully completed a $6.5 million public offering and received FDA clearance to include teen subjects in its Netherton Syndrome clinical trials.

Quoin Pharmaceuticals has announced the termination of contingent value rights (CVRs) related to the 2021 sale of Cellect Biotherapeutics, with no financial impact on Quoin.

Quoin Pharmaceuticals has entered into a purchase agreement with Alumni Capital LP for up to $8 million in funding through the sale of newly issued ordinary shares represented by American Depositary Shares.